Revolution Medicines’ Rasonque gains EC authorisation for pancreatic cancer
The decision permits use of the once-daily oral tablet in individuals with or without an identified RAS tumour mutation. Rasonque is a RAS(ON) multi-selective, noncovalent, tri-complex inhibitor. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.